Application of Angiogenesis to Clinical Dermatology

Advances in Dermatology

Volumn 24, Issue C, 2008, Pages 89-103

  Fried, Levi E ^a   Arbiser, Jack L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SKIN; SKIN DISEASE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SKIN; SKIN DISEASES;

EID: 56349097770     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2008.09.010     Document Type: Review

References (91)

1. Folkman J., Merler E., Abernathy C., et al. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133 (1971) 275-288
2. Fischer C., Jonckx B., Mazzone M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131 (2007) 463-475
3. Arbiser J.L. Angiogenesis and the skin: a primer. J Am Acad Dermatol 34 (1996) 486-497
4. Arbiser J.L., Karalis K., Viswanathan A., et al. Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J Invest Dermatol 113 (1999) 838-842
5. Arbiser J.L., Fine J.D., Murrell D., et al. Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Mol Med 4 (1998) 191-195
6. Jin D.K., Shido K., Kopp H.G., et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12 (2006) 557-567
7. Petit I., Jin D., and Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28 (2007) 299-307
8. Li S., Takeuchi F., Wang J.A., et al. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. J Exp Med 202 (2005) 617-624
9. Lyden D., Young A.Z., Zagzag D., et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401 (1999) 670-677
10. Sikder H., Huso D.L., Zhang H., et al. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 4 (2003) 291-299
11. Tanaka S., Mori M., Sakamoto Y., et al. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103 (1999) 341-345
12. Kalomenidis I., Kollintza A., Sigala I., et al. Angiopoietin-2 levels are elevated in exudative pleural effusions. Chest 129 (2006) 1259-1266
13. Hu B., Jarzynka M.J., Guo P., et al. Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway. Cancer Res 66 (2006) 775-783
14. Berger M., Bergers G., Arnold B., et al. Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood 105 (2005) 1094-1101
15. Hirschi K.K., Rohovsky S.A., and D'Amore P.A. PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 141 (1998) 805-814
16. Daly C., Pasnikowski E., Burova E., et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci U S A 103 (2006) 15491-15496
17. Fiedler U., Reiss Y., Scharpfenecker M., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12 (2006) 235-239
18. Voskas D., Jones N., Van S.P., et al. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol 166 (2005) 843-855
19. Lind A.J., Wikstrom P., Granfors T., et al. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 62 (2005) 394-399
20. Thurston G., Wang Q., Baffert F., et al. Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period. Development 132 (2005) 3317-3326
21. Kim I., Kim J.H., Moon S.O., et al. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene 19 (2000) 4549-4552
22. Hammes H.P., Lin J., Wagner P., et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 53 (2004) 1104-1110
23. Lee K.H., Lawley T.J., Xu Y.L., et al. VCAM-1-, ELAM-1-, and ICAM-1-independent adhesion of melanoma cells to cultured human dermal microvascular endothelial cells. J Invest Dermatol 98 (1992) 79-85
24. Mattila P., Majuri M.L., Mattila P.S., et al. TNF alpha-induced expression of endothelial adhesion molecules, ICAM-1 and VCAM-1, is linked to protein kinase C activation. Scand J Immunol 36 (1992) 159-165
25. Ockenhouse C.F., Tegoshi T., Maeno Y., et al. Human vascular endothelial cell adhesion receptors for Plasmodium falciparum-infected erythrocytes: roles for endothelial leukocyte adhesion molecule 1 and vascular cell adhesion molecule 1. J Exp Med 176 (1992) 1183-1189
26. Houstis N., Rosen E.D., and Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440 (2006) 944-948
27. Lambeth J.D. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4 (2004) 181-189
28. Babior B.M., and Curnutte J.T. Chronic granulomatous disease-pieces of a cellular and molecular puzzle. Blood Rev 1 (1987) 215-218
29. Dinauer M.C., Orkin S.H., Brown R., et al. The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature 327 (1987) 717-720
30. Bokoch G.M., and Zhao T. Regulation of the phagocyte NADPH oxidase by Rac GTPase. Antioxid Redox Signal 8 (2006) 1533-1548
31. Lopes N.H., Vasudevan S.S., Gregg D., et al. Rac-dependent monocyte chemoattractant protein-1 production is induced by nutrient deprivation. Circ Res 91 (2002) 798-805
32. Chen X.L., Zhang Q., Zhao R., et al. Superoxide, H2O2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase. Am J Physiol Heart Circ Physiol 286 (2004) H1001-H1007
33. Yu L., Zhen L., and Dinauer M.C. Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits. J Biol Chem 272 (1997) 27288-27294
34. Kwon J., Lee S.R., Yang K.S., et al. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A 101 (2004) 16419-16424
35. Govindarajan B., Klafter R., Miller M.S., et al. Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. Mol Med 8 (2002) 1-8
36. Shields J.M., Thomas N.E., Cregger M., et al. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res 67 (2007) 1502-1512
37. Fried L., and Arbiser J.L. The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res 21 (2008) 117-122
38. Govindarajan B., Sligh J.E., Vincent B.J., et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117 (2007) 719-729
39. Perry B.N., Govindarajan B., Bhandarkar S.S., et al. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol 126 10 (2006) 2316-2322
40. Cerimele F., Battle T., Lynch R., et al. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A 102 (2005) 175-179
41. Bhandarkar S.S., Mackelfresh J., Fried L., et al. Targeted therapy of oral hairy leukoplakia with gentian violet. J Am Acad Dermatol 58 (2008) 711-712
42. Arbiser J.L., Grossman K., Kaye E., et al. Use of short-course class 1 topical glucocorticoid under occlusion for the rapid control of erythrodermic psoriasis. Arch Dermatol 130 (1994) 704-706
43. Braverman I.M., and Sibley J. Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 78 (1982) 12-17
44. Malhotra R., Stenn K.S., Fernandez L.A., et al. Angiogenic properties of normal and psoriatic skin associate with epidermis, not dermis. Lab Invest 61 (1989) 162-165
45. Braverman I.M., and Sibley J. The response of psoriatic epidermis and microvessels to treatment with topical steroids and oral methotrexate. J Invest Dermatol 85 (1985) 584-586
46. Detmar M., Brown L.F., Claffey K.P., et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180 (1994) 1141-1146
47. Kunstfeld R., Hirakawa S., Hong Y.K., et al. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 104 (2004) 1048-1057
48. Wrone-Smith T., and Nickoloff B.J. Dermal injection of immunocytes induces psoriasis. J Clin Invest 98 (1996) 1878-1887
49. Nickoloff B.J., Xin H., Nestle F.O., et al. The cytokine and chemokine network in psoriasis. Clin Dermatol 25 (2007) 568-573
50. Nickoloff B.J., Bonish B.K., Marble D.J., et al. Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Investig Dermatol Symp Proc 11 (2006) 16-29
51. Zenz R., Eferl R., Kenner L., et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437 (2005) 369-375
52. Ma H.L., Liang S., Li J., et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 118 (2008) 597-607
53. Fitch E., Harper E., Skorcheva I., et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 9 (2007) 461-467
54. Elder J.T. IL-15 and psoriasis: another genetic link to Th17?. J Invest Dermatol 127 (2007) 2495-2497
55. Li J., Chen X., Liu Z., et al. Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sci Technolog Med Sci 27 (2007) 330-332
56. Zheng Y., Danilenko D.M., Valdez P., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445 (2007) 648-651
57. Zaba L.C., Cardinale I., Gilleaudeau P., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204 (2007) 3183-3194
58. Kimball A.B., Gordon K.B., Langley R.G., et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 144 (2008) 200-207
59. Gottlieb A.B., Matheson R.T., Lowe N., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139 (2003) 1627-1632
60. Tyring S., Gordon K.B., Poulin Y., et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143 (2007) 719-726
61. Arbiser J.L., Govindarajan B., Battle T.E., et al. Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J Invest Dermatol 126 (2006) 1396-1402
62. Zheng Y., Niyonsaba F., Ushio H., et al. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils. Br J Dermatol 157 (2007) 1124-1131
63. Buchau A.S., and Gallo R.L. Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol 25 (2007) 616-624
64. Takahashi K., Mulliken J.B., Kozakewich H.P., et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93 (1994) 2357-2364
65. Williams R.L., Risau W., Zerwes H.G., et al. Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell 57 (1989) 1053-1063
66. Cerimele F., Brown L.F., Bravo F., et al. Infectious angiogenesis: Bartonella bacilliformis infection results in endothelial production of angiopoetin-2 and epidermal production of vascular endothelial growth factor. Am J Pathol 163 (2003) 1321-1327
67. Verma A., and Ihler G.M. Activation of Rac, Cdc42 and other downstream signalling molecules by Bartonella bacilliformis during entry into human endothelial cells. Cell Microbiol 4 (2002) 557-569
68. Yu Y., Varughese J., Brown L.F., et al. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 159 (2001) 2271-2280
69. Chiller K.G., Frieden I.J., and Arbiser J.L. Molecular pathogenesis of vascular anomalies: classification into three categories based upon clinical and biochemical characteristics. Lymphat Res Biol 1 (2003) 267-281
70. Perry B., Banyard J., McLaughlin E.R., et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol 143 (2007) 504-506
71. Shirazi F., Cohen C., Fried L., et al. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol 5 (2007) 233-236
72. Lawley L.P., Cerimele F., Weiss S.W., et al. Expression of Wilms tumor 1 gene distinguishes vascular malformations from proliferative endothelial lesions. Arch Dermatol 141 (2005) 1297-1300
73. Cohen C., Zavala-Pompa A., Sequeira J.H., et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8 (2002) 3728-3733
74. Govindarajan B., Bai X., Cohen C., et al. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 278 (2003) 9790-9795
75. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95 5 (2006) 581-586
76. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
77. Varker K.A., Biber J.E., Kefauver C., et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14 (2007) 2367-2376
78. Arbiser J.L., Fan C.Y., Su X., et al. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. J Invest Dermatol 123 (2004) 788-790
79. Arbiser J.L., Byers H.R., Cohen C., et al. Altered basic fibroblast growth factor expression in common epidermal neoplasms: examination with in situ hybridization and immunohistochemistry. J Am Acad Dermatol 42 (2000) 973-977
80. Meeran S.M., Katiyar S., Elmets C.A., et al. Interleukin-12 deficiency is permissive for angiogenesis in UV radiation-induced skin tumors. Cancer Res 67 (2007) 3785-3793
81. Yusuf N., Nasti T.H., Long J.A., et al. Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res 68 (2008) 615-622
82. Arbiser J.L. Why targeted therapy hasn't worked in advanced cancer. J Clin Invest 117 (2007) 2762-2765
83. Kolhe N., Mamode N., Van der W.J., et al. Regression of post-transplant Kaposi's sarcoma using sirolimus. Int J Clin Pract 60 (2006) 1509-1512
84. Campistol J.M., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77 (2004) 760-762
85. Campistol J.M., and Schena F.P. Kaposi's sarcoma in renal transplant recipients-the impact of proliferation signal inhibitors. Nephrol Dial Transplant 22 Suppl 1 (2007) i17-i22
86. Fife K., Howard M.R., Gracie F., et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 9 (1998) 751-755
87. Cooley T., Henry D., Tonda M., et al. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist 12 (2007) 114-123
88. Krown S.E. Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. Hematol Oncol Clin North Am 17 (2003) 763-783
89. Shaw R.N., Arbiser J.L., and Offermann M.K. Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells. AIDS 14 (2000) 899-902
90. Klass C.M., Krug L.T., Pozharskaya V.P., et al. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 105 (2005) 4028-4034
91. Bhandarkar S.S., Cohen C., Kuruvila M., et al. Angiogenesis in cutaneous lesions of leprosy: implications for treatment. Arch Dermatol 143 (2007) 1527-1529